Nasdaq · Healthcare
Ultragenyx Pharmaceutical Inc. (RARE)
As-reported financials and recent SEC filings for Ultragenyx Pharmaceutical Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$673.0M
Net income
$-575.0M
Net margin
-85.4%
Diluted EPS
$-5.83
ROE
718.8%
P/E (TTM)
—
Market cap
$3.03B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $351.4M |
| Gross profit | — | — | — | — | — |
| Operating income | $-535.0M | $-536.0M | $-569.0M | $-648.9M | $-381.7M |
| Net income | $-575.0M | $-569.0M | $-607.0M | $-707.4M | $-454.0M |
| Diluted EPS | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-15
View on EDGAR →1442026-06-15
View on EDGAR →42026-06-15
View on EDGAR →42026-06-15
View on EDGAR →S-82026-06-12
View on EDGAR →1442026-06-01
View on EDGAR →42026-06-01
View on EDGAR →1442026-05-18
View on EDGAR →Go deeper on RARE
Search Ultragenyx Pharmaceutical Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.